Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Bazargan S, Bunch B, Ojwang' AME, Blauvelt J, Landin A, Ali J, Abrahams D, Cox C, Hall AM, Beatty MS, Poch M, Rejniak KA, Pilon-Thomas S.
Bazargan S, et al. Among authors: rejniak ka.
Front Immunol. 2023 Oct 12;14:1275375. doi: 10.3389/fimmu.2023.1275375. eCollection 2023.
Front Immunol. 2023.
PMID: 37901214
Free PMC article.